1. International Variations in Bladder Cancer Incidence and Mortality
  2. Risk of Several Cancers is Higher in Urban Areas after Adjusting for Socioeconomic Status. Results from a Two-Country Population-Based Study of 18 Common Cancers
  3. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review
  4. Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides
  5. Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
  6. Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
  7. Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant
  8. Stratifying patients with haematuria into high or low risk groups for bladder cancer: a novel clinical scoring system
  9. Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: time period-related comparison between Japan and Western countries
  10. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
  11. Identification of Mutations in Distinct Regions of p85 Alpha in Urothelial Cancer
  12. Killed but Metabolically Active Mycobacterium bovis BCG retains the antitumor ability of live BCG
  13. Individualized management of advanced bladder cancer: Where do we stand?
  14. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer
  15. Racial variation in the quality of surgical care for bladder cancer
  16. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological studies
  17. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients
  18. Muscle-Invasive Bladder Cancer: Evaluating Treatment and Survival in the National Cancer Data Base
  19. Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop
  20. Myths and mysteries surrounding bacillus calmette-guérin therapy for bladder cancer
  21. Induction chemotherapy followed by surgery in node positive bladder cancer
  22. Dietary patterns and risk of urinary tract tumors: a multilevel analysis of individuals in rural and urban contexts
  23. The Association of Hospital Volume With Conditional 90-day Mortality After Cystectomy: An Analysis of the National Cancer Database
  24. Neoadjuvant Chemotherapy for Bladder Cancer Does Not Increase Risk of Perioperative Morbidity
  25. Comparison of expected treatment outcome provided by risk models and international guidelines with observed treatment outcome in a cohort of Dutch non-muscle-invasive bladder cancer patients treated with intravesical chemotherapy
  26. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years
  27. Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers
  28. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder
  29. Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device
  30. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer
  31. Office-based management of nonmuscle invasive bladder cancer
  32. Incidence and Predictors of Understaging in Patients with Clinical T1 Urothelial Carcinoma Undergoing Radical Cystectomy
  33. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer
  34. Office-based ultrasound for the urologist
  35. Should Antibiotics Be Given Prior to Outpatient Cystoscopy? A Plea to Urologists to Practice Antibiotic Stewardship
  36. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
  37. Recent advances in diagnosis and treatment of transitional cell carcinoma of the bladder
  38. Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer
  39. Biomarkers in bladder cancer: Translational and clinical implications
  40. Prostate histoscanning in clinically localized biopsy proven prostate cancer - an accuracy study
  41. Patient-reported outcomes for patients undergoing radical cystectomy: a prospective case-control study
  42. Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes
  43. Long-Term Renal Function Outcomes after Radical Cystectomy
  44. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
  45. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
  46. Bladder cancer and arsenic through drinking water: a systematic review of epidemiologic evidence
  47. Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
  48. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder
  49. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients
  50. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis
  51. The complexity of bladder cancer: long noncoding RNAs are on the stage
  52. Clinicopathological Analysis of Patients with Non-muscle-invasive Bladder Cancer: Prognostic Value and Clinical Reliability of the 2004 WHO Classification System
  53. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer
  54. Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
  55. Radical cystectomy for treating bladder cancer: oncological outcome in 271 Chinese patients
  56. Current intravesical therapy for non-muscle invasive bladder cancer
  57. Is Urinary Soluble Fas an Independent Predictor of Non-Muscle-Invasive Bladder Cancer? A Prospective Chart Study
  58. Age, tumour stage, and preoperative serum albumin level are independent predictors of mortality after radical cystectomy for treatment of bladder cancer in Hong Kong Chinese
  59. Complementary and alternative medicine (CAM) in prostate and bladder cancer
  60. A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen)
  61. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review
  62. Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study
  63. Trimodality bladder preservation therapy for muscle-invasive bladder cancer
  64. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer
  65. Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
  66. Effect of laminin 332 on motility and invasion in bladder cancer
  67. The evolving understanding of microRNA in bladder cancer
  68. Refining Patient Selection for Neoadjuvant Chemotherapy Before Radical Cystectomy
  69. Presence of detrusor muscle in bladder tumor specimens-predictors and effect on outcome as a measure of resection quality
  70. Muscle Invasive Bladder Cancer: Examining Survivor Burden and Unmet Needs
  71. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
  72. Intravesical chemo-immunotherapy in Non Muscle Invasive Bladder Cancer
  73. Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies
  74. Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients
  75. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy
  76. Concurrence of villous adenoma and non-muscle invasive bladder cancer arising in the bladder: a case report and review of the literature
  77. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver
  78. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response
  79. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent
  80. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer
  81. Validation of RiskCheck Bladder Cancer?©, version 5.0 for risk-adapted screening of bladder cancer
  82. A randomized pilot trial of dietary modification for the chemoprevention of noninvasive bladder cancer: the dietary intervention in bladder cancer study
  83. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer
  84. Urinary markers for bladder cancer
  85. Post-intravesical BCG epididymo-orchitis: Case report and a review of the literature
  86. Is TURBT able to cure high risk recurrent superficial or muscle invasive bladder cancer: factors resulting in pT0 radical cystectomy specimens
  87. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer
  88. Quality of Life in Patients with Ileal Conduit Cystectomy Due to Bladder Cancer
  89. Optimal use and outcomes of orthotopic neobladder reconstruction in men and women
  90. Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
  91. A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine
  92. Higher surgeon and hospital volume improves long-term survival after radical cystectomy
  93. Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
  94. Optimizing systemic therapy for bladder cancer
  95. Preoperative risk factors related to bladder cancer rehabilitation: a registry study
  96. Dual role of TGFBR3 in bladder cancer
  97. Validation Study of a Noninvasive Urine Test for Diagnosis and Prognosis Assessment of Bladder Cancer: Evidence for Improved Models
  98. Sex differences in incidence and mortality of bladder and kidney cancers: National estimates from 49 countries
  99. Characterization of texture features of bladder carcinoma and the bladder wall on MRI: initial experience
  100. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
  101. Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies
  102. Immediate Post-Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non-Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review
  103. Challenging boundaries: an enhanced recovery programme for radical cystectomy
  104. Impact of fluid intake in the prevention of urinary system diseases: a brief review
  105. UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy
  106. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility
  107. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3)
  108. Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature
  109. Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis
  110. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature
  111. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective?
  112. Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
  113. Shift work and cancer research: a thought experiment into a potential chronobiological fallacy of past and perspectives for future epidemiological studies
  114. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies
  115. Obesity and Risk of Bladder Cancer: A Meta-analysis of Cohort Studies
  116. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
  117. Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study
  118. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades
  119. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey
  120. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research
  121. Biomarkers for assessing therapeutic response in bladder cancer
  122. Effect of statin use on outcomes of non-muscle-invasive bladder cancer
  123. In-hospital mortality and failure-to-rescue rates after radical cystectomy
  124. Biophysical Characterization of Bladder Cancer Cells with Different Metastatic Potential
  125. The role of methylation in urological tumours
  126. Elective Bladder-Sparing Treatment for Muscle Invasive Bladder Cancer
  127. Insulin Use and Smoking Jointly Increase the Risk of Bladder Cancer Mortality in Patients With Type 2 Diabetes
  128. Systemic Absorption and Pharmacokinetics of Single-dose Early Intravesical Mitomycin C After Transurethral Resection of Non-muscle-invasive Bladder Cancer
  129. Impact of 18 F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle
  130. Practice-based collaboration to improve the use of immediate intravesical therapy after resection for non-muscle-invasive bladder cancer
  131. Introduction of online adaptive radiotherapy for bladder cancer through a multicentre clinical trial (Trans-Tasman Radiation Oncology Group 10.01): Lessons learned
  132. Treatment of Non Muscle Invasive Bladder Tumor Related to the Problem of Bacillus Calmette-Guerin Availability. Consensus of a Spanish Expert's Panel
  133. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors
  134. Dietary sources of N-nitroso compounds and bladder cancer risk: Findings from the Los Angeles bladder cancer study
  135. Hypoxia regulates FGFR3 expression via HIF-1? and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer
  136. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
  137. Is photodynamic diagnosis ready for introduction in urological clinical practice?
  138. Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer
  139. Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC)
  140. Current status of minimally invasive radical cystectomy: an outcome-based comparison
  141. The SPARC (Survival Prediction After Radical Cystectomy) Score: A Multifactorial Outcome Prediction Model for Patients Undergoing Radical Cystectomy for Bladder Cancer
  142. Predicting Recurrence and Progression in Chinese Patients With Nonmuscle-invasive Bladder Cancer Using EORTC and CUETO Scoring Models
  143. Dipping technique for ureteroileal anastomosis in orthotopicilealneobladder: 20-year experience in 670 patients-no stenosis with preservation of the upper tract
  144. Gene expression profile and enrichment pathways in different stages of bladder cancer
  145. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostatfor treatment of bladder cancer
  146. Improving bladder cancer patient care: a pharmacoeconomic perspective
  147. Utility of 67Ga Scintigraphy in Disseminated Infection After BCG Instillation for Treatment of Bladder Carcinoma
  148. Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder
  149. Karnofsky Performance Status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma
  150. Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?
  151. Performing Radical Cystectomy and Urinary Diversion in Regional Anesthesia: Potential Risk Reduction in the Treatment of Bladder Cancer
  152. Time between First and Second Transurethral Resection of Bladder Tumors in Patients with High-Grade T1 Tumors: Is It a Risk Factor for Residual Tumor Detection?
  153. Expression and role of miR-34a in bladder cancer
  154. Prostate-Sparing Radical Cystectomy for Selected Patients with Bladder Cancer
  155. CEUS in the differentiation between low and high-grade bladder carcinoma
  156. Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3?/Snail signaling
  157. Quantitative changes in p53, Bcl-2 and apoptosis in blood and urine of bladder cancer patients
  158. Evaluation of urinary human telomerase reverse transcriptase mRNA and scatter factor protein as urine markers for diagnosis of bladder cancer
  159. Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation
  160. A New Algorithm for Integrated Analysis of miRNA-mRNA Interactions Based on Individual Classification Reveals Insights into Bladder Cancer
  161. Diabetes Mellitus Increases the Risk of Bladder Cancer: An Updated Meta-analysis
  162. Quality of care indicators and their related outcomes: A population-based study in prostate cancer patients treated with radiotherapy
  163. Bladder cancer epidemiology and genetic susceptibility
  164. Survival Impact of Follow-up Care after Radical Cystectomy for Bladder Cancer
  165. Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer
  166. Holmium laser versus conventional transurethral resection of the bladder tumor
  167. Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy
  168. Biological and Statistical Approaches for Modeling Exposure to Specific Trihalomethanes and Bladder Cancer Risk
  169. Efficacy and safety of photodynamic therapy in recurrent high-grade non-muscle-invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy
  170. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53
  171. Egg consumption and risk of bladder cancer: a meta-analysis
  172. Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis
  173. Fusion of planning CT and cystoscopy images for bladder tumor delineation: a feasibility study
  174. The Study of DNA Methylation in Urological Cancer: Present and Future
  175. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer
  176. Zinc and copper levels in bladder cancer: a systematic review and meta-analysis
  177. DNA methylation-based biomarkers in bladder cancer
  178. Inhibition of presenilins attenuates proliferation and invasion in bladder cancer cells through multiple pathways
  179. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics
  180. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk
  181. Independent prognostic factors for initial intravesical recurrence after laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma
  182. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer
  183. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer
  184. Environmental non-occupational risk factors associated with bladder cancer
  185. Id-like reaction to BCG therapy for bladder cancer
  186. Rosiglitazone is not associated with an increased risk of bladder cancer
  187. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia
  188. A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder
  189. Incidental cancer of the prostate in patients with bladder urothelial carcinoma: comprehensive analysis of 1476 radical cystoprostatectomy specimens
  190. Height as an Explanatory Factor for Sex Differences in Human Cancer
  191. The use of the decision tree technique and image cytometry to characterize aggressiveness in World Health Organization (WHO) grade II superficial transitional cell carcinomas of the bladder
  192. Maintenance Bacillus Calmette-Guérin Treatment of Non-muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence
  193. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma
  194. Treatment of urethral/bladder neck stricture after high-intensity focused ultrasound for prostate cancer with holmium: yttrium-aluminium-garnet laser
  195. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma
  196. Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy?
  197. Gene expression study related with the intrinsic pathway of apoptosis in bladder cancer by real-time PCR technique
  198. Bladder cancer in individuals with spinal cord injuries
  199. Bladder cancer-induced skeletal muscle wasting: Disclosing the role of mitochondria plasticity
  200. Estrogen receptor-? expression and pharmacological targeting in bladder cancer
  201. SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Non-Muscle Invasive Bladder Cancer Who Recurred Following at Least Two Prior Courses of Intravesical BCG
  202. Concurrent bladder lymphoma and bladder cancer presenting as metastatic bladder cancer
  203. Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
  204. Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma
  205. Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients
  206. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value
  207. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis
  208. Bladder cancer
  209. Cost Effectiveness of Fluorescence in Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma
  210. EAU Guidelines on Primary Urethral Carcinoma
  211. Outcome of urinary bladder recurrence after partial cystectomy for en bloc urinary bladder adherent colorectal cancer resection
  212. Advances in bladder cancer imaging
  213. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer
  214. Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy
  215. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer
  216. The Treatment of Recurrent Urothelial Tumors of the Upper Urinary System and at Urostomy Site following Radical Cystectomy with Intraureteral Bacillus Calmette-Guérin and Cryotherapy
  217. Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer
  218. miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2
  219. Is gender becoming relevant in uro-oncological research? A bibliographical analysis
  220. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression
  221. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer
  222. Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions
  223. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)
  224. Premalignant lesions of the urinary bladder
  225. Multidisciplinary management of patients with localized bladder cancer
  226. BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model
  227. Risk Factors for Intravesical Recurrence in Patients with High-grade T1 Bladder Cancer in the Second TUR Era
  228. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results
  229. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC)
  230. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer
  231. Low RKIP expression associates with poor prognosis in bladder cancer patients
  232. microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer
  233. Defining good candidates for extraperitoneal cystectomy: results from random peritoneum biopsies of 136 cases
  234. Spontaneous rupture of urinary bladder: a case report and review
  235. Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk
  236. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies
  237. The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder
  238. Is cystoscopy indicated for incidentally identified bladder wall thickening?
  239. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array-based DNA methylation and expression profiling
  240. Dietary consumption and diet diversity and risk of developing bladder cancer: results from the South and East China case-control study
  241. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer
  242. Management of superficial and muscle-invasive urothelial cancers of the bladder
  243. The Association Between Self-Reported Diabetes and Cancer Incidence in the NIH-AARP Diet and Health Study
  244. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer
  245. Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
  246. A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer
  247. Prognostic significance of tumor location and superficial urothelial bladder carcinoma history in patients with ureteral urothelial carcinoma treated with radical nephroureterectomy
  248. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer
  249. Long-term Outcomes of Robot-assisted Radical Cystectomy for Bladder Cancer
  250. Impact of Statin Use on Oncological Outcomes of Patients with Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy
  251. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: Results from a prospective lymph node mapping study
  252. Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer
  253. Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011
  254. High-grade non-muscle-invasive bladder cancer: Is re-resection necessary in all patients before intravesical bacillus Calmette-Guérin treatment?
  255. Therapeutic options for intractable hematuria in advanced bladder cancer
  256. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
  257. Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells
  258. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder?
  259. A prospective comparative study of intravesical Bacillus Calmette-Guérin therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer
  260. Does phosphorylation of cofilin affect the progression of human bladder cancer?
  261. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder
  262. Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer
  263. Predicting progression of bladder urothelial carcinoma using microRNA expression
  264. Relationship of vitamin d monitoring and status to bladder cancer survival in veterans
  265. Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical Cystectomy: preliminary results
  266. "BCGitis": A rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guérin therapy
  267. Bladder cancer: a simple model becomes complex
  268. Real-time bladder lesion registration and navigation: a phantom study
  269. Survival analysis of patients with bladder cancer, life table approach
  270. Systematic Assessment of Complications and Outcome of Radical Cystectomy Undertaken with Curative Intent in Patients with Comorbidity and over 75 Years of Age
  271. Update on use of Enhanced Imaging to Optimize Lymphadenectomy in Patients Undergoing Minimally Invasive Surgery for Urothelial Cancer of the Bladder
  272. Statin use and risk of bladder cancer: a meta-analysis
  273. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer
  274. Estrogen receptor ? (ER?) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch
  275. The association of tea consumption with bladder cancer risk: a meta-analysis
  276. 'Omics' approaches to understanding interstitial cystitis/painful bladder syndrome/bladder pain syndrome
  277. Photodynamic effect of 5-aminolevulinic acid-loaded nanoparticles on bladder cancer cells: A preliminary investigation
  278. Comparison of microscopic (pT3a) and gross extravesical extension (pT3b) in pathological staging of bladder cancer: analysis of patient outcomes
  279. Association of p53 Arg72Pro polymorphism with bladder cancer: a meta-analysis
  280. Perioperative Complications and Mortality After Radical Cystectomy When Using a Standardized Reporting Methodology
  281. Adjuvant Methods to Improve Results of Local Bladder Irrigations by Chemotherapy for NMIBC
  282. Childbearing and the Risk of Bladder Cancer: A Nationwide Population-based Cohort Study
  283. Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case-control study
  284. The Impact of Perioperative Blood Transfusion on Cancer Recurrence and Survival Following Radical Cystectomy
  285. Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
  286. ppGalNAc T1 as a Potential Novel Marker for Human Bladder Cancer
  287. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: A report from the Los Angeles Cancer Surveillance Program
  288. Comparative Performance of Comorbidity Indices for Estimating Perioperative and 5-Year All-Cause Mortality Following Radical Cystectomy for Bladder Cancer
  289. BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model
  290. Genetic variations in microRNA-biogenesis genes and clinical outcomes in non-muscle invasive bladder cancer
  291. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer?
  292. Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives
  293. Evaluation of a bladder cancer cluster in a population of criminal investigators with the bureau of alcohol, tobacco, firearms and explosives-part 1: the cancer incidence
  294. Maintenance Therapy with Intravesical Bacillus Calmette-Guerin in Patients with Intermediate- or High-risk Non-muscle-invasive Bladder Cancer
  295. A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness
  296. Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer
  297. Imatinib radiosensitises bladder cancer by targeting homologous recombination
  298. Immunohistochemical evaluation of cell cycle regulators: impact on predicting prognosis in stage t1 urinary bladder cancer
  299. Single cell network profiling assay in bladder cancer
  300. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study
  301. Efficacy and safety of hexaminolevulinate fluorescence cystoscopy in the diagnosis of bladder cancer
  302. Standardization of diagnostic biomarker concentrations in urine: the hematuria caveat
  303. Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients
  304. Therapeutic Effects of MicroRNA-582-5p and -3p on the Inhibition of Bladder Cancer Progression
  305. Management of high-risk non-muscle invasive bladder cancer
  306. Centrosome amplification in bladder washing cytology specimens is a useful prognostic biomarker for non-muscle invasive bladder cancer
  307. Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience
  308. Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumours at diagnosis
  309. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen
  310. Lymph node dissection in bladder cancer. Impact on staging and prognosis
  311. "Never Events": Centers for Medicare and Medicaid Services Complications After Radical Cystectomy
  312. Nitrate in drinking water and bladder cancer: A meta-analysis
  313. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis
  314. Prognostic Value of the Lymphovascular Invasion in High-Grade Stage pT1 Bladder Cancer
  315. Med19 promotes bone metastasis and invasiveness of bladder urothelial carcinoma via bone morphogenetic protein 2
  316. Perivascular epithelioid cell neoplasm of the urinary bladder in an adolescent: a case report and review of the literature
  317. A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
  318. Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy
  319. The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes
  320. Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer
  321. Comparison of adaptive radiotherapy techniques for the treatment of bladder cancer
  322. Investigational cell cycle inhibitors in clinical trials for bladder cancer
  323. Current pre-clinical models for the advancement of translational bladder cancer research
  324. The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer
  325. Egg intake and bladder cancer risk: A meta-analysis
  326. An evaluation to define the role of repeat transurethral resection in a treatment algorithm for non-muscle-invasive bladder cancer
  327. Genetic variations in the transforming growth factor Beta pathway as predictors of bladder cancer risk
  328. Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer
  329. Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers
  330. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer
  331. Emerging personalized approaches for the management of advanced urothelial carcinoma
  332. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis
  333. Comparison of Surveillance Strategies for Low-Risk Bladder Cancer Patients
  334. Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy
  335. Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis
  336. Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio
  337. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
  338. Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy
  339. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection
  340. Brief Smoking Cessation Intervention: A Prospective Trial in the Urology Setting
  341. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
  342. MAGE-A10 cancer/testis antigen is highly expressed in high grade non muscle invasive bladder carcinomas
  343. Prognostic Risk Stratification of Patients with Urothelial Carcinoma of the Urinary Bladder who Developed Recurrence after Radical Cystectomy
  344. MR Imaging of Urinary Bladder Carcinoma and Beyond
  345. Follow-up procedures for non-muscle-invasive bladder cancer: an update
  346. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis
  347. Current perspectives in bladder cancer management
  348. Examining the safety of PPAR agonists - current trends and future prospects
  349. A multi-analyte assay for the non-invasive detection of bladder cancer
  350. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: A systematic review and meta-analysis
  351. Long-term survival outcomes with intravesical docetaxel in the management of recurrent non-muscle-invasive bladder cancer (NMIBC) after previous BCG therapy
  352. The Association of RAS Association Domain Family Protein1A (RASSF1A) Methylation States and Bladder Cancer Risk: A Systematic Review and Meta-Analysis
  353. Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients
  354. Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma
  355. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
  356. Nodal staging score: A tool for survival prediction of node-negative bladder cancer
  357. FGFR3 mutation analysis on voided urine samples to reduce cystoscopies and cost in non-muscle invasive bladder cancer surveillance: a comparison of three different strategies
  358. FDG-PET/CT in Monitoring Response of Pelvic Lymph Node Metastases to Neoadjuvant Chemotherapy in Bladder Cancer
  359. Outcomes Following Radical Cystectomy For Nested Variant of Urothelial Carcinoma: A Matched Cohort Analysis
  360. MAGE-A10 cancer/testis antigen is highly expressed in high grade non muscle invasive bladder carcinomas
  361. Prognostic Risk Stratification of Patients with Urothelial Carcinoma of the Urinary Bladder who Developed Recurrence after Radical Cystectomy
  362. MR Imaging of Urinary Bladder Carcinoma and Beyond
  363. Follow-up procedures for non-muscle-invasive bladder cancer: an update
  364. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis
  365. Current perspectives in bladder cancer management
  366. Examining the safety of PPAR agonists - current trends and future prospects
  367. A multi-analyte assay for the non-invasive detection of bladder cancer
  368. Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: A systematic review and meta-analysis
  369. Long-term survival outcomes with intravesical docetaxel in the management of recurrent non-muscle-invasive bladder cancer (NMIBC) after previous BCG therapy
  370. The Association of RAS Association Domain Family Protein1A (RASSF1A) Methylation States and Bladder Cancer Risk: A Systematic Review and Meta-Analysis
  371. Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients
  372. Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma
  373. The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer
  374. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection
  375. The Sensitivity of Initial Transurethral Resection or Biopsy of Bladder Tumor(s) in Detecting Bladder Cancer Variants on Radical Cystectomy
  376. Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer
  377. Measuring Priority Symptoms in Advanced Bladder Cancer: Development and Initial Validation of a Brief Symptom Index
  378. Meta-analysis demonstrates lack of association of the hOGG1 Ser326Cys polymorphism with bladder cancer risk
  379. Association of p53 Arg72Pro polymorphism with bladder cancer: A meta-analysis
  380. Identification of lymphatic pathway involved in the spread of bladder cancer: Evidence obtained from fluorescence navigation with intraoperatively injected indocyanine green
  381. Prognostic Value of Perinodal Lymphovascular Invasion Following Radical Cystectomy for Lymph Node-positive Urothelial Carcinoma
  382. Interobserver Agreement of Confocal Laser Endomicroscopy for Bladder Cancer
  383. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers
  384. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology
  385. High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment
  386. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression
  387. Economic and Humanistic Consequences of Preventable Bladder Tumor Recurrences in Nonmuscle Invasive Bladder Cancer Cases
  388. Understanding the Use of Immediate Intravesical Chemotherapy for Patients with Bladder Cancer
  389. Bladder interstitial cells: an updated review of current knowledge
  390. Management of non-muscle-invasive (superficial) bladder cancer
  391. Prognostic value of cell-cycle regulation biomarkers in bladder cancer
  392. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer
  393. Current role of radiation therapy for bladder cancer
  394. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience
  395. Treatment-Related Morbidity in Prostate Cancer: A Comparison of 3-Dimensional Conformal Radiation Therapy With and Without Image Guidance Using Implanted Fiducial Markers
  396. Innovations in radical cystectomy and pelvic lymph node dissection
  397. Inhibition of bladder cancer by broccoli isothiocyanates sulforaphane and erucin: Characterization, metabolism, and interconversion
  398. Current strategies in the treatment of non-muscle-invasive bladder cancer
  399. Radiologic imaging of patients with bladder cancer
  400. Smoking and Survival After Radical Cystectomy for Bladder Cancer
  401. Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review
  402. A contemporary update on pathology reporting for urinary bladder cancer
  403. Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation
  404. Assessing The Invasive Potential Of Bladder Cancer: Development And Validation Of A New Preclinical Assay
  405. A Meta-Analysis of Tea Consumption and the Risk of Bladder Cancer
  406. Preoperative Staging of Invasive Bladder Cancer With Dynamic Gadolinium-enhanced Magnetic Resonance Imaging: Results From a Prospective Study
  407. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer
  408. Association of Bowel Habits with Lower Urinary Tract Symptoms in Adult Men: Findings from the 2005-2006 and 2007-2008 National Health and Nutrition Examination Survey (NHANES)
  409. A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin
  410. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer
  411. Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: A single center randomized controlled trial
  412. Copper, Zinc, and Cu/Zn Ratio in Transitional Cell Carcinoma of the Bladder
  413. Perioperative Outcomes and Oncologic Efficacy from a Pilot Prospective Randomized Clinical Trial of Open versus Robotic Assisted Radical Cystectomy
  414. Prognostic Significance of Measured Depth of Invasion of Urothelial Carcinoma of the Bladder Compared to the 2010 American Joint Committee on Cancer pT2 and pT3 Classifications
  415. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance
  416. ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion
  417. Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
  418. Type 2 diabetes mellitus, insulin use, and risk of bladder cancer in a large cohort study
  419. Bladder conservation for muscle-invasive bladder cancer
  420. Physical activity and urologic cancers
  421. Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy
  422. Narrow-band imaging cystoscopy in non-muscle-invasive bladder cancer: a prospective comparison to the standard approach
  423. Cyclooxygenase-2 Expression in Bladder Cancer and Patient Prognosis: Results from a Large Clinical Cohort and Meta-Analysis
  424. Comorbidities of bladder pain syndrome/interstitial cystitis: a population-based study
  425. Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute
  426. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer
  427. Connaught and Russian showed the highest direct antitumoral effects among different BCG substrains
  428. Association of human herpes, papilloma and polyoma virus families with bladder cancer
  429. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
  430. Discovery of Potential Bladder Cancer Biomarkers by Comparative Urine Proteomics and Analysis
  431. Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect
  432. Retrospective Analysis of Clinical Outcomes With Neoadjuvant Cisplatin-Based Regimens for Muscle-Invasive Bladder Cancer
  433. Diagnosis of bladder cancer by immunocytochemical detection of minichromosome maintenance protein-2 in cells retrieved from urine
  434. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy
  435. Thermochemotherapy for Non-Muscle-Invasive Bladder Cancer: Is There a Chance to Avoid Early Cystectomy?
  436. Comparative Outcomes of Primary, Recurrent, and Progressive High-risk Non-muscle-invasive Bladder Cancer
  437. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis.
  438. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer
  439. Twist Confers Chemoresistance to Anthracyclines in Bladder Cancer through Upregulating P-Glycoprotein
  440. Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol
  441. Meta-Analysis Shows Strong Positive Association of the TNF-α Gene with Tumor Stage in Bladder Cancer
  442. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy
  443. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy
  444. Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review
  445. Clinical features of bladder cancer in primary care
  446. Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: A potential improvement of intravesical chemotherapy in bladder cancer
  447. Urinary levels of Hepatocarcinoma-intestine-pancreas/Pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer
  448. ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate
  449. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer
  450. Treatment Options Available for Bacillus Calmette-Guérin Failure in Non-muscle-invasive Bladder Cancer
  451. Extravasation of Intravesical Chemotherapy for Non-Muscle-Invasive Bladder Cancer
  452. Cost-effective treatment of low-risk carcinoma not invading bladder muscle
  453. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition
  454. Watchful Waiting Versus Intravesical BCG Therapy for High-grade pT1 Bladder Cancer with pT0 Histology After Second Transurethral Resection: Japan Clinical Oncology Group Study JCOG1019
  455. The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study
  456. Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours
  457. Carboplatin Based Induction Chemotherapy for Nonorgan Confined Bladder Cancer-A Reasonable Alternative for Cisplatin Unfit Patients?
  458. A Novel Molecular Grading Model: Combination of Ki67 and VEGF in Predicting Tumor Recurrence and Progression in Non-invasive Urothelial Bladder Cancer
  459. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings
  460. Clinicopathological spectrum and the outcome of treatment of upper tract transitional cell carcinoma
  461. Targeted agents in second-line bladder cancer therapy
  462. Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis
  463. Surgical and Chemotherapeutic Management of Regional Lymph Nodes in Bladder Cancer
  464. Research Progress in Potential Urinary Markers for the Early Detection, Diagnosis and Follow-up of Human Bladder Cancer
  465. P53 Arg72Pro Polymorphism and Bladder Cancer Risk - Meta- analysis Evidence for a Link in Asians but not Caucasians
  466. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges
  467. Role of chronic E. coli infection in the process of bladder cancer- an experimental study
  468. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis
  469. Detection of bladder cancer using proteomic profiling of urine sediments
  470. Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study
  471. Epidemiology and Risk Factors of Urothelial Bladder Cancer
  472. Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival
  473. Oncolytic viruses in the treatment of bladder cancer
  474. Urine telomerase for diagnosis and surveillance of bladder cancer
  475. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention
  476. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression
  477. Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival
  478. Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria
  479. Role of C-reactive protein in urological cancers: A useful biomarker for predicting outcomes
  480. Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer
  481. A Noninvasive Multianalyte Urine-Based Diagnostic Assay for Urothelial Cancer of the Bladder in the Evaluation of Hematuria
  482. Fluorescence diagnosis of bladder cancer: a novel in vivo approach using 5-aminolevulinic acid (ALA) dendrimers
  483. Recent advances in urinary bladder cancer detection
  484. Biomarkers for bladder cancer aggressiveness
  485. Acute Arthritis Secondary to Intravesical Bacillus Calmette-Guérin for Bladder Cancer
  486. Increased risk of bladder cancer following diagnosis with bladder pain syndrome/interstitial cystitis
  487. Epigenetic Alterations in Bladder Cancer and Their Potential Clinical Implications
  488. The Value of Transurethral Bladder Biopsy after Intravesical Bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer: A Retrospective, Single Center Study and Cumulative Analysis of the Literature
  489. High-risk nonmuscle invasive bladder cancer: definition and epidemiology
  490. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis
  491. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer
  492. Pathological possibilities and pitfalls in detecting aggressive bladder cancer
  493. Arterial Bleeding during Transurethral Resection of Bladder Cancer Managed by Endovascular Intervention
  494. Statin use and the risk of bladder cancer: a population-based case-control study
  495. An association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer in non-smokers: a meta-analysis
  496. Multivariate analysis of the prognostic significance of resection weight after transurethral resection of bladder tumor for non-muscle-invasive bladder cancer
  497. Prognostic Value of Renin-Angiotensin System Blockade in Non-muscle-invasive Bladder Cancer
  498. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo
  499. Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Using EORTC Risk Tables
  500. Bladder Cancer Immunotherapy: BCG and Beyond
  501. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey
  502. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study